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ABSTRACT
Objectives: Using anti-androgenic contraception is one of the methods of birth control. It also has a significant, non-con-
traceptive impact on women’s body. These drugs can be used in various endocrinological disorders, because of their ability 
to reduce the level of male hormones.
The aim of our study is to establish a correlation between taking different types of anti-androgenic drugs and intensity of 
hirsutism, acne, menstrual pain intensity and sexuality . 
Material and methods: 570 women in childbearing age that had been using oral contraception for at least three months 
took part in our research. We examined women and asked them about quality of life, health, direct causes and effects of 
that treatment, intensity of acne and menstrual pain before and after. Our research group has been divided according to 
the type of gestagen contained in the contraceptive pill: dienogest, cyproterone, chlormadynone and drospirenone. Ad-
ditionally, the control group consisted of women taking oral contraceptives without antiandrogenic component. 
Results: The mean age of the studied group was 23 years ± 3.23. 225 of 570 women complained of hirsutism. 
The mean score for acne intensity before the use of contraception was 2.7 ± 1.34. The mean score for acne intensity after 
3 months of using contraception was 1.85 ± 1.02 (p < 0.001). 192 women reported excess hairiness in one or more area 
before treatment. Mean value based on Ferriman-Gallway scale before the treatment was 6.23 ± 6.21 and 5.39 ± 5.6 after 
the treatment (p < 0.001).
Conclusions: All groups of drugs effectively reduced pain and acne severity. Cyproterone and drospirenone turned out 
as the most effective drugs in treating hirsutism. Surprisingly, according to our research, dienogest does not have any 
impact on body hairiness. 
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INTRODUCTION
Hyperandrogenaemia is a very frequent endocrinopathy. 
It concerns about 7% of women in childbearing age. Its clini-
cal symptoms can be pretty troublesome and often affect our 
patients’ self-esteem. Oral contraceptives, many times viewed 
only as a method of contraception, turn out to be very useful 
in those conditions and offer a variety of non-contraceptive 
health benefits. They are becoming more and more popular 
in women with higher levels of androgens. Additionally, they 
reduce menstrual pain and the amount of blood loss during 
the menstruation. Moreover, taking hormonal contraceptives 
regulates the menstrual cycle [1].
Hyperandrogenaemia can be caused by different 
disease entities, for example polycystic ovary syndrome, 
obesity, Cushing syndrome, ovarian secreting androgens, 
adrenal tumors, adrenal hyperplasia, liver insufficiency. The 
most common symptoms connected with higher levels of 
androgens are hirsutism and acne. Hirsutism affects about 
5–15% and acne about 6–55% of women, according to 
epidemiological data [1].
Physiologically, androgens are responsible for hair 
growth regulation, production and secretion of gonado-
tropins, wound healing and cutaneous barrier formation. 
The pathogenesis of acne and hirsutism in hyperandroge-
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naemia is connected with sebaceous glands, hair follicles 
and enzymatic reactions in them. Androgens are converted 
into the dihydrotestosterone (DHT) which has 5 to 10 times 
higher affinity to androgen receptor than testosterone [1].
The involvement of androgens in acne vulgaris is support-
ed by different evidences such as lack of acne in men with an-
drogen insensitivity or responding in reduced sebum produc-
tion in women with acne using antiandrogenic drugs. It is also 
known, that androgens are responsible for the replacement of 
vellus hair, which are slight and unpigmented, by thicker and 
darker terminal hair. That is observed in androgen-sensitive 
areas and happens in hyperandrogenic entities. Therefore, it 
seems to be justified to use drugs that decrease the level of 
male hormones, to help with those complaints [2, 3].
For now, two types of oral contraceptives are known: com-
bined and progestin-only. Combined hormonal contracep-
tives are very effective in skin changes, whereas progestin-only 
contraception may even worsen the condition of the skin [1].
One of the types of oral contraceptives are antiandro-
genic oral contraceptive pills. They are combined hormonal 
contraceptives that consist of two components: estrogen 
and progestogen. The mechanism of action of those drugs 
concentrates on decreasing the level of androgens in four 
ways. Firstly, inhibition of secretion of gonadotropins, mostly 
the luteinizing hormone (LH). This mechanism is the main 
reason for using antiandrogenic pills in ovarian hyperan-
drogeneamia, especially hyperthecosis. Then, those drugs 
increase the liver synthesis of sex hormone binding globu-
line (SHBG), which ends up with a higher level of bounded 
androgens and reduced level of biologically active male hor-
mones. Moreover, they decrease the adrenal androgens syn-
thesis, and finally, reduce the activity of androgen receptors.
Antiandrogenic hormonal pills can be divided into 
four groups depending on the type of progestogen: dr-
ospirenone, chlormadynone, cyproterone and dienogest.
Drospirenone
Drospirenone is a derived form of 17 alfa-spironolactone 
and has a similar chemical structure to spironolactone. It is 
mostly bounded to albumin, so that the free blood amount 
is about 3–5%. Despite having anti-mineralocorticoid and 
anti-androgenic activity, which is almost 30% of the anti-andro-
genic activity of cyproterone acetate, drospirenone has diverse 
metabolic effects such as potential to reduce blood pressure 
and weight loss. The overall pearl index of the combined ethi-
nylestradiol/drospirenone contraceptive is 0.64 [4, 5].
Chlormadyinone
Chlormadyinone acetate is one of derived form of pro-
gesterone. Studies have shown its high efficiency in treat-
ment of acne, comparing to other anti-androgenic hormonal 
pills. This contraceptive is well tolerated and shows a reliable 
contraceptive effect. The overall pearl index of the combined 
ethinylestradiol/chlormadinone contraceptive is 0.34 [6, 7].
Cyproterone acetate (CPA)
Cyproterone acetate (CPA) is the most common anti-an-
drogenic drug prescribed to patients with PCOS. According 
to researches, there are no significant differences in mecha-
nism of action between types of those drugs, but CPA seems 
to play a significant role in women with high LH/FSH ratio. 
On the other hand, cyproterone acetate should be pre-
scribed wisely, because of its side effects. According to differ-
ent studies, CPA should not be used only as a contraceptive. 
It can be prescribed in specific complaints like moderate to 
severe acne and hirsutism in women in reproductive age, 
but only if alternative treatments, such as topical therapy 
and systemic antibiotic treatment, have failed [4, 8].
Dienogest
Dienogest is the only nortestosterone derivative with 
antiandrogenic potency. Its antiandrogenic activity is meas-
ured as about 30% of cyproterone acetate activity. Only 
10% of dienogest is bond to SHBG or CBG so that high 
serum levels are achieved. Moreover, dienogest is known 
as a proven way to treat endometriosis, as it has tolerable 
profile, minimal side effects, it is safe for long-term use and 
lowers the risk of recurrence of endometriosis. The overall 
pearl index of the combined ethinylestradiol/dienogest 
contraceptive is 0.21 [5, 9, 10].
Despite many positive aspects of oral contraception, 
it should be avoided in women suffering from migraine 
headache, systemic lupus erythematosus, cholecystic dis-
eases, crescent cell anemia, mitral valve prolapse and item 
in patients who smokes cigarettes, hyperlipidemiae, arterial 
hypertension, who had in past gestational diabetes and me-
chanical jaundice during pregnancy. The contraindications 
to that treatment are as follows: pregnancy, breast feeding, 
birth canal bleeding with unknown etiology, estrogen-de-
pendent cancers, circulatory system and hepatic diseases, 
migraine treated by ergotamine, significant hypercholes-
terolemia or hypertriglyceridemia and smoking after age 
of 35 years [1, 11]. 
 Of course, the possible harmful effects of oral contracep-
tion should also be considered. Other side effects reported 
with hormonal contraception is breast tension, headaches, 
nausea, irregular menses, weight growth, diminished libido 
and depression [12]. Therefore, prescribing oral contracep-
tives to the patient should always be carefully thought out.
The aim of the study was to establish the correlation 
between the type of active progestogen ingredient in oral 
antiandrogenic contraception and reducing hirsutism in 
specific areas, reducing intensity of pain and acnes in wo-
mens body for 3-month follow-up period. 
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MATERIAL AND METHODS
This prospective, observational, non-interventional study 
was carried out at the Department of Pregnancy Pathology, 
Department of Woman’s Health, School of Health Sciences 
in Katowice, Medical University of Silesia, Poland between 
March 2018 and March 2019. Patients were recruited person-
ally while waiting for their routine medical check-ups. Women 
above eighteen years old, in childbearing age and non-preg-
nant were enrolled to our study. Patients with indications for 
use of oral contraception, who had given permission for the 
beginning of hormonal therapy took part in our research. 
Exclusion criteria were using oral hormonal contraception or 
another drug with antiandrogenic component, for example 
finasteride and flutamide, for at least three past months and 
lack of patient’s consent. Finally, 570 patients were included 
into the study. The university Ethics Committee waived the 
requirement for informed consent due to the anonymous and 
non-interventional nature of the study (KNW/0022/KB/68/19). 
Patients gave informed consent to the study.
 The completely self-administered questionnaire was 
provided to the patients twice. At the first visit we asked 
about gynecological, endocrinological and general medical 
conditions, menorrhea disorders, used medicaments and 
intensity of menstrual pain. Information about relationship, 
habitation, education and quality of life were also collected. 
Physical examination contained weight and height meas-
urement, evaluation of intensity of acne and hairiness in 
9 androgen sensitive areas — upper lip, chin, chest, upper 
and lower back, upper and lower abdomen, upper arms and 
thighs. Based on results of examination hirsutism assessment 
with Ferriman-Gallwey (FG) scoring were done. Hair growth 
was marked in all of those areas on scale from 0 (no terminal 
hair) to 4 (maximal growth). The maximum score is 36. Women 
with a score of 8 and more were diagnosed with hirsutism [13]. 
During three weeks before evaluation patients were request-
ed not to use shaving or other mode of hair removal. Patients 
were prescribed oral contraception. According to the type 
of active ingredient women were divided into five groups: 
control group (patients using oral contraceptives without 
anti-androgenic component) and four research groups, de-
pending on active progestogen substance (Fig. 1).
After three months patients were asked to visit the out-
patient clinic again in order to re-evaluate the score in the 
Ferriman-Gallwey scale. Rules of not shaving for three weeks 
before the evaluation were persistent. The intensity of acne 
was marked. Questions about the intensity of menstrual 
pain were also asked.
All data analyses were conducted using StatSoft Statistica 
version 13.0 PL software and P value of < 0.05 was considered 
as significant. Quantitative variables are presented as mean and 
standard deviation (SD) or a median and interquartile range 
(IQR). The qualitative variables are presented as an absolute val-
ue and/or percentage. Between-group differences for quantita-
tive variables were verified using parametric (t-test or ANOVA) 
or non-parametric tests (Mann-Whitney U or Kruskal-Wallis), 
with previous verification of their distribution by the Shap-
iro-Wilk or Kolmogorov-Smirnov test. In the case of qualitative 
variables, the chi-square test or Fisher’s exact test were used.
RESULTS
The mean age of the patients was 23 years ± 3.23. Their 
average age in both of groups was similar. Table 1 presents 
general characteristics of the studied group (Tab. 1). 
Figure 1. Patients’ oral contraception intake divided by type of 
gestagen
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Table 1. Subjects’ characteristics.
Research 
group
Control 
group p
Age [years] 23 ± 3.04 23 ± 3.9 > 0.05
Martial status
Married 
Informal relationship
Single
66 (14.5%)
294 (64.5%)
96 (21%)
15 (13.15%)
89 (78.1%)
10 (8.8%)
> 0.05
Education 
University degree
 High school
 Vocational
 No education
171 (37.5%)
280 (61.4%)
5 (1.1%)
1 (0.02%)
44 (38.6%)
68 (59.7%)
2 (1.7%)
0 (0%)
> 0.05
Place of residence
City above 200,000 residents
City 50,000–200,000 residents
Town below 50,000 residents
Village
222 (48.7%)
77 (16.9%)
59 (12.9%)
98 (21.5%)
67 (58.8%)
24 (21.1%)
11 (9.7%)
12 (10.5%)
> 0.05
Living conditions
 Very good
 Good
 Average
 Below the average
199 (43.6%)
202 (44.3%)
54 (11.8%)
1 (0.2%)
53 (46.5%)
48 (42.1%)
13 (11.4%)
0 (0%)
> 0.05
Growth [cm] 167 ± 7.14 167 ± 6.01 > 0.05
Weight [kg] 62 ± 12.2 59 ± 8.54 > 0.05
Data are presented as number (%) or mean SD
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Pain and acne
The mean score for acne intensity before the use of 
contraception was 2.7 ± 1.34. The mean score for acne 
intensity after 3 months of using contraception was 
1.85 ± 1.02 (p < 0.001). The intensity of acne before and 
after the use of contraception in each group is presented 
in Figure 2. The reduction of acne intensity was statistically 
important in all five groups (p < 0.001). 
The mean score of menstruation pain intensity before 
the use of contraception was 6.15 ± 2.55. The mean score 
of pain intensity after 3 months of using contraception was 
2.96 ± 1.92 (p < 0.001). The intensity of pain before and 
after the use of contraception in each group is presented 
in Figure 3. All of anti-androgenic groups and control group 
reduce the intensity of menstrual pain in  three months 
period (p < 0.001). 
Hirsutism 
The mean score based on Ferriman-Gallway scale in 
the studied group was 2.1 ± 4.65 before the treatment and 
1.83 ± 4. 12 after the treatment (p < 0.001). 
378 women (66.32%) did not report excess hairiness 
in any part of the body before the treatment (0 points). 
386 patients (67.72%) didn’t report excess hairiness after 
the treatment (0 points). 
192 women reported excess hairiness in one or more area 
before treatment. Mean value based on Ferriman-Gallway 
scale before the treatment was 6.23 ± 6.21 and 5.39 ± 5.6 af-
ter the treatment (p < 0.001). In this group, 59 of women had 
a score of 8 or more, in a scale Ferriman-Gallway this result 
is regarded as hirsutism. 
Table 2 presents the intensity of excessive hairiness in 
the group of 192 women who reported excessive hairiness 
in one or more parts of the body before the treatment, 
depending on the type of contraception.
Effects of the treatment on hirsutism in different parts 
of the body are shown in Table 3. Cyproterone reduces 
hairiness on chin (p = 0.04), thighs (p = 0.05) and buttocks 
(p = 0.04). Drospirenone has the effect of reducing excessive 
hair on upper lip (p = 0.01), thighs (p = 0.04) and buttocks 
(p = 0.04). Chlormadinone has statistically important impact 
on underbelly and thighs (p = 0.01) hirsutism. After three 
months of using control group the p value is important for 
upper lip (p = 0.04). On the other hand, dienogest does not 
contribute to decrease body hairiness in any of the chosen 
areas (p > 0.05 for each part of the body).
DISCUSSION
 Hyperandrogenism is a complex condition that can man-
ifest in different clinical symptoms such as hirsutism, acne 
and others, which often result in lower self-esteem. For now, 
we know that oral antiandrogenic pills are helpful, but are 
prescribed rather randomly because the main differences 
between ways and places of action are still not known [14].
Although it is unclear how the biochemical markers of 
hyperandrogenism affect the quality of patients’ life, study 
shows that the clinical manifestations play the main role 
in worsening it. That is probably because the severity of 
symptoms in hyperandrogenism correlate poorly with the 
androgen excess and some of the patients with clinical 
symptoms of hyperandrogenism have androgen levels in 
normal ranges. That is why it is important to choose the 
treatment that can help with patients’ complaint, not only 
the biochemical markers [15].
Table 2. Mean value of excessive hairiness in the group of 
192 women who reported excessive hairiness in one or more parts 
of the body before the treatment
Before After p
Dienogest 2.43 ± 5.38 2.06 ± 4.88 < 0.001
Cyproterone 3.71 ± 5.5 3.48 ± 4.88 < 0.001
Chlormadynone 1.96 ± 4.93 1.73 ± 4.55 < 0.001
Drospirenone 1.7 ± 4.25 1.35 ± 3.34 < 0.001
Control group 0.91 ± 2.36 0.79 ± 2.19 < 0.001
Data are presented as mean ± SD
Figure 2. The intensification of acne before and after treatment
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Figure 3. The intensification of the menstrual pain before and after 
treatment
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Polycystic ovarian syndrome (PCOS) is a common gyne-
cologycal problem that affects about 5–9 % of women in 
reproductive age. Rotterdam criteria ESHRE/ASRM are used 
to define that condition. They include clinical or biochemi-
cal hyperandrogenism, infrequent or absence of ovulation 
and polycystic ovaries on ultrasound [17]. It is necessary 
to exclude other disorders with androgen excess. Ovaries 
and adrenals are responsible for increased androgen level 
in PCOS. The excess of testosterone (T), total, unbound and 
free form can be found. Also, that disorder can be related 
to high level of Δ4-Androstendione (Δ4-A), dehydroepian-
drosterone (DHEA), and DHEAsulfate (DHEAS). It turned out 
that testosterone is a superior marker of hyperadnogenemia. 
Free testosterone and Δ4-Androstendione are also impor-
tant, but less than testosterone. Many women who are suf-
fering from PCOS had increased level of testosterone and 
normal free testoserone and Δ4-Androstendione. Increased 
Δ4-A level can be associated with more severe phenotype 
of PCOS [16–19].
One of the studies, examined the effects of different 
physical training protocols on the sexual function of women 
with PCOS. This research revealed that continuous aerobic 
training as well as intermittent aerobic training increased the 
quality of sexual life and reduced the anxiety and depression 
of women with polycystic ovary syndrome [20]. According 
to that study, women suffering from hyperandrogenism and 
its clinical symptoms are less satisfied with their sexual life. 
It turned out that choosing oral antiandrogenic contracep-
tion containing chlormadinone acetate cause the change 
in sexual behavior during the treatment. Patients found 
themselves to be more sexually attractive and as well their 
partners found them more sexually attractive than before. 
That is probably because of the aesthetic improvement 
obtained by the pill intake. More researches are needed to 
be done to find out if other groups of antiandrogenic pills 
have similar impact on women’s sexual behavior [21, 22].
One of the studies analyzed the influence of genotype 
and hyperandrogenism on sexual function, gender identi-
fication, and partner preference in women with congenital 
adrenal hyperplasia (CAH) who present symptoms of hy-
perandrogenism [23]. This study is pointing to importance 
of early beginning of antiandrogenic treatment in women 
with congenital adrenal hyperplasia [23]. 
This study is only a prototype for comparison between 
the four groups of antiandrogenic drugs. It is focused on 
searching the differences between place of action in hir-
sutism. That means the treatment probably can be matched 
to specific problems more precisely, limiting the side effects 
to the minimum for every woman’s case. 
According to our research the most effective in hir-
sutism are drospirenone and cyproterone so that they would 
be the best for patients with polycystic ovary syndrome. 
A systematic review is pointing to similar effectiveness 
of these two drugs [24]. They reduce hairiness mostly on 
thighs, buttock and accordingly on upper lip and chin. Ad-
ditionally, dienogest statistically does not have any impact 
on body hairiness. Other study confirms that dienogest is 
worse in reducing hirsutism than cyproterone [25]. That 
can suggest withdrawal of prescribing it to women with 
those complaints. Chlormadinone has impact only on 
underbelly and thighs excessive hair. According to study 
these antiandrogenic drug is effective in hirsutism, but less 
than drospirenone [1].
It is important to remember that the most common 
symptom of polycystic ovary syndrome is moderate and 
severe acne. There, gyneacologist should always take into 
consideration all of the symptoms that patient complaints 
of and try to find a solution to all of them. However, this 
research did not indicate any important differences in 
reducing intensity of menstrual pain and acne. All of the 
antiandrogenic groups and control group seem to have 
similar impact on those complaints. That is why matching 
Table 3. The intensification of the hirsutism before and after treatment
Part of the 
body
Dienogest Cyproterone Chlormadynone Drospirenone Control group
Before After p-value Before After p-value Before After p-value Before After p-value Before After p-value
Upper lip 2.22 1.815 > 0.05 1.571 1.375 > 0.05 1.773 1.55 > 0.05 1.931 1.625 0.01 1.444 1.125 0.04
Chin 1.294 1.200 > 0.05 1.667 1.571 0.04 2.286 2.444 > 0.05 1.182 1.182 > 0.05 1.143 1.00 > 0.05
Chest 2.200 1.667 > 0.05 1.000 1.00 > 0.05 1.000 0 > 0.05 1.500 1.556 > 0.05 1.250 1.00 > 0.05
Stomach 1.529 1.467 > 0.05 1.500 1.667 > 0.05 1.733 1.600 > 0.05 1.563 1.375 > 0.05 1.222 1.300 > 0.05
Underbelly 2.083 2.000 > 0.05 1.667 1.556 > 0.05 2.316 1.895 0.01 1.778 1.444 > 0.05 1.389 1.400 > 0.05
Arms 1.833 2.000 > 0.05 1.667 1.667 > 0.05 2.571 2.571 > 0.05 1.667 1.400 > 0.05 1.667 1.667 > 0.05
Thighs 1.857 1.650 > 0.05 2.500 2.167 0.05 2.235 1.765 0.01 2.214 1.857 0.04 1.875 1.625 > 0.05
Back 2.000 2.000 > 0.05 1.500 1.500 > 0.05 0 0 0 1.400 1.000 > 0.05 1.000 1.000 > 0.05
Buttocks 3.182 2.818 > 0.05 2.400 2.500 0.04 2.800 2.800 > 0.05 2.667 2.429 0.04 2.333 1.750 >0.05
Data are presented as mean ± SD
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the specific group of drug to specific hirsutism area probably 
can be independent of other popular factors, excluding the 
side effects [16].
Polycystic ovary-related hyperandrogenic symptoms 
can by effectively treated by cyproterone acetate and ethi-
nylestradiol (CPA/EE). Besides all the over obvious effects 
such as improvement in hirsutism, acne, seborrhea, alopecia, 
irregular bleeding and decrease in hyperandrogenemia and 
hyperinsulinemia, this treatment may result in reduction in 
risk of ovarian, colon and endometrial cancer. There are also 
researches, which indicate that short-term pre-treatment 
CPA/EE could potentially increase fertility in female patients 
and improve pregnancy outcomes, however more studies 
are needed [26].
Considering lipid and glucose metabolism cyproter-
one acetate and ethinylestradiol seems to be better choice 
for patient with polycystic ovary syndrome, because this 
condition is associated with multitude of metabolic disor-
ders. Androgenic progestogens such as levonorgestrel may 
have negative influence on metabolism parameters [26, 27]. 
The side effects or hormonal contraception should be 
always taken into consideration, prudent usage of medica-
ments with cyproterone is justified and the balance between 
profits and side effects needs to be kept [12, 28].
CONCLUSIONS
The main finding from this study was different impact on 
reducing hirsutism in specific areas depending on used drug: 
dienogest, cyproterone, chlormadinone or drospirenone. 
It means that the treatment can be precisely matched to 
specific woman’s problem. The biggest impact on chin hair 
had cyproterone. To reduce hirsute intensity on upper lip 
prime choice could be drospirenone and oral contraception 
without antiandrogen component. If thigh area is the most 
problematic for the patient, she should take cyproterone, 
drospirenone or chlormadinone. The best treatment for but-
tocks hairiness is cyproterone or drospirenone and for lower 
abdomen — chlormadinone. According to this research, 
dienogest does not have important influence on hirsutism.
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